KINAXO Launches Enhanced KinaTor(TM) Cellular Profiling Service
Martinsried, Germany, 8th October 2007. KINAXO Biotechnologies today
announced that it has added quantitative analysis to its KinaTor(TM)
chemical proteomics platform tailored for the cellular profiling of
kinase inhibitors.
The enhanced KinaTor(TM) Cellular Profiling Service enables KINAXO's
pharmaceutical and biotechnology clients to make more informed
decisions on which drug candidates to progress into advanced
pre-clinical development.
The KinaTor(TM) Cellular Profiling Service platform may be employed
in a number of further applications including target identification,
drug reprofiling and drug rescue. Commenting on the launch of the new
service Dr Andreas Jenne KINAXO's CEO said: "KINAXO is delighted to
announce this significant development in the capabilities of our
successful KinaTor(TM) platform. We look forward to putting the
enhanced KinaTor(TM) Cellular Profiling Service to work for our
existing and future clients.'"
KINAXO's quantitative KinaTor(TM) Cellular Profiling Service utilizes
proprietary chemical proteomics technologies combined with
state-of-the-art mass spectrometry to identify not only the drug
candidate's native molecular targets from cellular samples but also
the affinities of these interactions. This data provides a valuable
insight into the drug candidate's in vivo molecular target profile.
The technology was developed by Dr Henrik Daub and Professor Axel
Ullrich of the Max Planck Institute of Biochemistry in Martinsried
and has been exclusively licensed by its technology transfer
organization Max Planck Innovation to KINAXO
Biotechnologies. Commenting on the new service, Dr Klaus Godl
KINAXO's CSO said; "It is critically important that all biological
interactions of a kinase inhibitor are evaluated, not just those with
a subset of recombinant kinases. The new service will enable not only
the identification of drug candidate interactions with proteins
derived from real cellular samples but importantly also their
affinities thus supporting more informed lead candidate selection."
About KINAXO
KINAXO Biotechnologies is a privately-held biotechnology company
based in Munich/Martinsried, Germany. We support pharmaceutical and
biotechnology companies in their development and optimization of drug
leads. Amongst others KINAXO has ongoing collaborations with UCB
Pharma and Johnson & Johnson. KINAXO offers its clients a
comprehensive chemical-proteomics platform - known as KinaTor(TM) -
that identifies and characterizes the interaction of small molecule
inhibitors with their cellular protein targets. Tailored to protein
kinases, the KinaTor(TM) technology supports more informed lead
candidate selection. Licensing agreements with GPC Biotech AG and the
Max Planck Society provides KINAXO Biotechnologies GmbH with
exclusive worldwide rights to use the KinaTor(TM) technology in
contract research activities.
Contact
Dr. Andreas Jenne, CEO, KINAXO Biotechnologies GmbH, Am Klopferspitz
19a, 82152 Martinsried, Germany, info@kinaxo.de, +498946133630,
www.kinaxo.com
